Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure.

Slides:

Advertisements

Similar presentations

1. 2 Accreditation and Designation of Credit The Network for Continuing Medical Education ( NCME) is accredited by the Accreditation Council for Continuing.

Advertisements

Frank Svec, MD, PhD Clinical Professor of Medicine Tulane University School of Medicine New Orleans, Louisiana Kevan Chambers Announcer Medscape Diabetes.

Advances in Pharmacotherapy with a Focus on Combination Therapy Louis J. Aronne, MD, FACP Clinical Professor of Medicine Weill Cornell Medical College.

What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.

Katee Lira, PharmD PGY2 Ambulatory Care Pharmacy Resident

Diabetes Update Matt Bouchonville, MD Endocrinology Division University of New Mexico ACP New Mexico Chapter Scientific Meeting November 7, 2014

JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes

Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.

A. Update on Type 2 Diabetes

Faculty Disclosure Mikayla Spangler, PharmD, BCPS Dr. Spangler has listed no financial interest/arrangement that would be considered a conflict of interest.

Why Surgical Treatment of Diabetes May Not be a Good Option McGill First Canadian Summit on Surgery for Type 2 Diabetes Montréal, Québec May 7, 2010 David.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Barriers to Diabetes Control Mark E. Molitch, MD.

Afrezza® – inhaled human insulin

UK/TB/0213/0017a February 2013 New treatment options Dr Craig Parkinson.

Reducing the Risk of T2DM: What Works?

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.

Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.

Toujeo® and it’s Place in Therapy

Diabetes Update Part 2 of 3 Division of Endocrinology

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Endocrine and Metabolic Drugs Advisory Committee Meeting - Human Recombinant.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach Part 2 1.

New Insulin Formulations

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 2 of 4.

Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

Therapy of Type 2 Diabetes Mellitus: UPDATE

EXUBERA® (insulin [rDNA origin] powder for inhalation) Endocrinologic and Metabolic Drugs Advisory Committee Meeting September 8, 2005 Dr. Neville Jackson.

Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

© 2013 Eli Lilly and Company Managing insulin therapy in Insulin resistance Speaker name and affiliation Prescribing information is available on the last.

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 4 of 4.

Insulin degludec (Tresiba®)

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added.

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 2 of 5.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

A The BYETTA mark and the BYETTA design mark are trademarks of Amylin Pharmaceuticals, Inc. All other trademarks are property of their respective.

Supported by Virtual Poster Hall: Summary Slides Professor Stephan Matthaei Tuesday, September 15 th This Virtual Poster Hall session explores the relationship.

Diagnosing Diabetes Mellitus in Adults: Type 1, LADA, Type 2 Stanley Schwartz MD, FACE, FACP Affiliate, Main Line Health System Emeritus, Clinical Assoc.

Copyright © 2015 by the American Osteopathic Association.

NATURAL HISTORY OF BETA CELL FAILURE IN T2DM

Copyright © 2015 by the American Osteopathic Association.

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 4.

Copyright © 2015 by the American Osteopathic Association.

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 3.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use David M. Kendall, MD, Robert M. Cuddihy, MD,

Athena Philis-Tsimikas, MD The American Journal of Medicine

Acknowledgments and Disclosures

Pramlintide Synthetic analog of the β-cell hormone amylin

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Selected efficacy and safety parameters.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Pramlintide Therapy Part 1of 2

Effect of empagliflozin on efficacy parameters at week 18.

Glycemic control and body weight over 52 weeks.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: NAME OF PRESENTER: Curtis Triplitt, PharmD, CDE Speaker’s Bureau: Amylin, Eli Lilly, Novartis, Takeda Board Member/Advisory Panel: Amylin, Eli Lilly

Treating Type 2 DM in the 21 st Century Curtis Triplitt, PharmD, CDE Texas Diabetes Institute Asst. Professor, Dept. of Medicine/ Div. of Diabetes Clinical Assistant Professor of Pharmacy University of Texas Health Science Center San Antonio, Texas

Presentation not available due to pending publication and intellectual property issues.

The following references were used: Pathophysiologic Basis of Treatment: Adapted from Inzucchi SE. JAMA. 2002;287: Factors that Influence the Efficiency of Inhaled Insulin: Nature Reviews Drug Discovery 1; (2002) Exubera Inhaled Insulin Change-Baseline FEV1 in T1DM: September 8, 2005, EMDAC Meeting, Food and Drug Administration Exubera Inhaled Insulin Change-Baseline DLCO in Type 1 DM - Pooled Phase 2 and 3 Studies: September 8, 2005, EMDAC Meeting, Food and Drug Administration Technosphere/MannKind Insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA (R) Inhaler: Diabetes Technology and Therapeutics 2002;4(5):589 Technosphere/MannKind Inhaled Insulin: Rosenstock J.et al. ADA Scientific Sessions. 2005, San Diego, CA: 357-OR When Does Beta-Cell Function Decline? Ferrannini, E. et al. J Clin Endocrinol Metab 2005;90: Initial Combination Therapy With Sitagliptin Plus Metformin Study: Design-Data available on request from Merck & Co., Inc. Please specify (1)-JAN. Initial Combination Therapy With Sitagliptin Plus Metformin Study: A1C Results Through 104 Wks (2 years): 1. Goldstein BJ et al. Diabetes Care. 2007;30(8):1979– Data available on request from Merck & Co., Inc. Please specify (1)-JAN. Study Results: Placebo-subtracted HbA 1c Reductions in Combination Therapy Studies- Williams-Herman D, et al. Abstract 875. Presented at the 19th World Diabetes Congress, 3–7 December 2006, Cape Town, South Africa. Liraglutide’s Impact on Glucagon Secretion inType 2 Diabetes Mellitus- Degn KB, et al. Diabetes 2004, 53: Exenatide BID versus Exenatide QW- Drucker D, Buse JB, Taylor K et al. DURATION-1 trial online Lancet Sept DOI: /S (08) A1C: 52-Week Evaluable Population-A1C: 52-Week Evaluable Population- Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco,CA. FPG: 52-Week Evaluable Population-FPG: 52-Week Evaluable Population- Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA. Weight Loss Through Week 52-Weight Loss Through Week 52-Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA. Type 2 DM: Pancreatitis-1. Frey et al. Pancreas (4): Martinez et al. Pancreatology 2006;6: Liraglutide and Calcitonin- Thiazolidinediones- Nature Medicine 2005;11: Limb Fractures in Women with Rosiglitazone- J of Endocrinology 2004;183:203-16; Nature Medicine 2007;13: